Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ii-Key-H1 swine influenza vaccine
- Development stage
- Preclinical
- Lead developer
- Generex Biotechnology
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
The **Ii-Key-H1 swine influenza vaccine** is an experimental vaccine candidate developed by Generex Biotechnology in response to the 2009 H1N1 swine flu outbreak. It leverages the **Ii-Key technology**, a proprietary peptide-based platform that enhances MHC class II presentation of vaccine antigens to boost CD4+ T-cell responses and immunogenicity. The vaccine incorporates an H1 antigen derived or adapted from an existing H5 vaccine component, aiming to elicit protective immunity against swine influenza A H1N1 virus. Revitalized amid the pandemic, it represents an early-stage effort to improve peptide vaccine efficacy for rapid pandemic response, though no detailed clinical trial data or current development status is publicly documented.
- Other names
- Ii-Key-H1 peptide vaccineIi-Key-H-1 peptide vaccineIi-Key-H 1 peptide vaccineIi-Key peptide hybrid construct
02
Targets
H1 HA (Influenza A hemagglutinin H1)MHC II (Major histocompatibility complex class II receptor)HA (Hemagglutinin)
Beyond the preview
Go deeper on Ii-Key-H1 swine influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ii-Key-H1 swine influenza vaccine.